Myositis Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Myositis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 1

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting
Not Applicable

Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease

Myasthenia GravisAmyotrophic Lateral SclerosisNeuromuscular Diseases (NMD)+15 more
University of Missouri-Columbia50 enrolled1 locationNCT07478172
Recruiting

Rheumatology Patient Registry and Biorepository

Rheumatoid ArthritisLyme DiseaseSarcoidosis+17 more
Yale University5,000 enrolled1 locationNCT04402086
Recruiting
Phase 1

DR-0201 in Subjects With Autoimmune Diseases

SclerodermaSLEDermatomyositis+9 more
Dren Bio36 enrolled10 locationsNCT06647069
Recruiting

A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101

Multiple SclerosisRheumatoid Arthritis (RA)Dermatomyositis+4 more
Kyverna Therapeutics70 enrolled1 locationNCT07403188
Recruiting
Phase 2

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

SclerodermaRheumatoid Arthritis (RA)Sjogren Syndrome+6 more
Artiva Biotherapeutics, Inc.90 enrolled26 locationsNCT06991114
Recruiting
Not Applicable

Home Based Clinical Management of Interstitial Lung Disease in Systemic Rheumatic Diseases

Rheumatoid ArthritisConnective Tissue DiseasesDermatomyositis+3 more
Oslo University Hospital218 enrolled1 locationNCT06732674
Recruiting

Rheumatology Diet Study

Rheumatoid ArthritisFibromyalgiaAnkylosing Spondylitis+8 more
University of Central Florida500 enrolled1 locationNCT06339957
Recruiting

Rare AutoImmune SElf-management Programme Development

Sjogren SyndromeSystemic Lupus ErthematosusSystemic Sclerosis (SSc)+3 more
University of the West of England360 enrolled1 locationNCT06642870
Recruiting

ROLE of PLATELETS in the PATHOPHYSIOLOGY of SYSTEMIC LUPUS

Rheumatoid ArthritisSystemic Lupus ErythematosusSystemic Scleroderma Meeting+3 more
University Hospital, Strasbourg, France450 enrolled1 locationNCT06593041
Recruiting

Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease

MicrobiomeImmune FunctionAnti-MDA5 Antibody Positive Dermatomyositis
Chinese PLA General Hospital50 enrolled1 locationNCT06203249
Recruiting
Phase 1

Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease

DermatomyositisSystemic SclerodermaAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis+2 more
Chongqing Precision Biotech Co., Ltd24 enrolled1 locationNCT06056921